RxDoctor Payments Data

Richard Chase, DO

Family Medicine · Ideal, GANPI 1699718411

Payments from drug & device makers

$2,107in general payments, 2019–2025

Across 124 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$873
  • Novo Nordisk$330
  • Novartis$163
  • AstraZeneca$118
  • Lilly USA, LLC$113
  • Esperion Therapeutics, Inc.$112
  • plus $397 from 14 others

What the payments were for

  • Food & beverage$2,107100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,107 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$52,670
Medicare patients
397
Services billed
1,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban291$47,488
JardianceEmpagliflozin157$24,142
TrulicityDulaglutide23$22,965
RexultiBrexpiprazole17$22,535
JanuviaSitagliptin Phosphate122$17,443
NamzaricMemantine Hcl/Donepezil Hcl96$14,225
LinzessLinaclotide21$12,170
MyrbetriqMirabegron101$12,013
EntrestoSacubitril/Valsartan56$11,335
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,080
XareltoRivaroxaban56$9,222
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog59$7,691
Atorvastatin Calcium1,043$7,316
RestasisCyclosporine20$6,901
TrintellixVortioxetine Hydrobromide13$6,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Linzess, Restasis, Lumigan$27$36,264148 claims
Boehringer IngelheimJardiance$67$24,142157 claims
Lilly USA, LLCTrulicity$113$22,96523 claims
MerckJanuvia$47$17,443122 claims
GSKTrelegy Ellipta, Shingrix$873$13,78729 claims
NovartisEntresto$163$11,33556 claims
Avanir Pharmaceuticals, Inc.Nuedexta$16$5,90414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Ideal

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →